MedTrace Logo

Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma

NCT06644430 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 470

Last updated 2024-12-03

No results posted yet for this study

Summary

Ablation has been an effective therapy in treating intrathoracic metastases. However, for hepatocellular carcinoma with pulmonary oligometastasis, ablation of metastases remains relatively unexplored and still needs clinical evidence.

Conditions

Interventions

PROCEDURE

Ablation

Ablation including (microwave ablation, radiofrequency ablation, cryoblation), this surgery was conducted under CT guidence. The pulmonary was completely ablated.

DRUG

system therapy

Paticipants received systemic therapy according the instructions.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Feng Duan, MD · Chinese PLA General Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-04
Primary Completion
2025-06-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06644430 on ClinicalTrials.gov